Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

OptiNose, Inc. - Common Stock (NQ:OPTN)

9.170 +0.020 (+0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OptiNose, Inc. - Common Stock

< Previous 1 2 Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mr. Cooper Group Inc. (Nasdaq – COOP), Beacon Roofing Supply, Inc. (Nasdaq - BECN), Optinose, Inc. (Nasdaq - OPTN), Redfin Corporation (Nasdaq - RDFN)
From Brodsky & Smith LLC
Via GlobeNewswire
Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Beacon Roofing Supply, Inc. (Nasdaq – BECN), Optinose, Inc. (Nasdaq – OPTN), Corporation (Nasdaq – RDFN), Blackboxstocks Inc. (Nasdaq – BLBX)
From Brodsky & Smith LLC
Via GlobeNewswire
OPTN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Optinose, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders
From Ademi & Fruchter LLP
Via Business Wire
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results
Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% 
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces 1-for-15 Reverse Stock Split
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Optinose, Inc.
Via GlobeNewswire
Optinose Appoints Terry Kohler as Chief Financial Officer
From Optinose, Inc.
Via GlobeNewswire
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Expanded Access to XHANCE with Addition to National Commercial Formularies
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces $55 Million Registered Direct Offering
From Optinose, Inc.
Via GlobeNewswire
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the Needham Virtual Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.